Abstract
We investigated combining a core AD neuropathology measure (plasma amyloid-beta [Aβ] 42/40) with five plasma markers of inflammation, cellular stress, and neurodegeneration to predict cognitive decline. Among 401 participants free of dementia (median [IQR] age, 76 [73–80] years) from the Multidomain Alzheimer Preventive Trial (MAPT), 28 (7.0%) participants developed dementia, and 137 (34.2%) had worsening of clinical dementia rating (CDR) scale over 4 years. In the models utilizing plasma Aβ alone, a tenfold increased risk of incident dementia (nonsignificant) and a fivefold increased risk of worsening CDR were observed as each nature log unit increased in plasma Aβ levels. Models incorporating Aβ plus multiple plasma biomarkers performed similarly to models included Aβ alone in predicting dementia and CDR progression. However, improving Aβ model performance for composite cognitive score (CCS) decline, a proxy of dementia, was observed after including plasma monocyte chemoattractant protein 1 (MCP1) and growth differentiation factor 15 (GDF15) as covariates. Participants with abnormal Aβ, GDF15, and MCP1 presented higher CCS decline (worsening cognitive function) compared to their normal-biomarker counterparts (adjusted β [95% CI], − 0.21 [− 0.35 to − 0.06], p = 0.005). In conclusion, our study found limited added values of multi-biomarkers beyond the basic Aβ models for predicting clinically meaningful cognitive decline among non-demented older adults. However, a combined assessment of inflammatory and cellular stress status with Aβ pathology through measuring plasma biomarkers may improve the evaluation of cognitive performance.
Similar content being viewed by others
References
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021;397:1577–90.
Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimer’s Dement. 2019;15:776–87. https://doi.org/10.1016/j.jalz.2019.03.007.
Bjorkli C, Sandvig A, Sandvig I. Bridging the Gap between fluid biomarkers for Alzheimer’s disease, model systems, and patients. Front Aging Neurosci. 2020;12:272.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–62.
Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s Dement. 2017;13:841–9. https://doi.org/10.1016/j.jalz.2017.06.2266.
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–59. https://doi.org/10.1212/WNL.0000000000008081.
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol. 2019;76:1060–9. https://doi.org/10.1001/jamaneurol.2019.1632.
Hsu JL, Lee WJ, Liao YC, Wang SJ, Fuh JL. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease. Alzheimer’s Res Ther. 2017; 9. https://doi.org/10.1186/s13195-017-0319-x.
Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE, et al. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging. 2020;89:99–107. https://doi.org/10.1016/j.neurobiolaging.2020.01.007.
Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B. Assessment of plasma amyloid-β42/40 and cognitive decline among community-dwelling older adults. JAMA Netw open. 2020;3:e2028634. https://doi.org/10.1001/jamanetworkopen.2020.28634.
Iulita MF, Ganesh A, Pentz R, Flores Aguilar L, Gubert P, Ducatenzeiler A, Christie S, Wilcock GK, Cuello AC. Identification and preliminary validation of a plasma profile associated with cognitive decline in dementia and at-risk individuals: a retrospective cohort analysis. J Alzheimer’s Dis. 2019;67:327–41.
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015, 14, 388–405.
Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonça VA, Gattaz WF, Forlenza OV. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Alzheimer’s Dis. 2010;22:1305–11. https://doi.org/10.3233/JAD-2010-100921.
Gross AL, Walker KA, Moghekar AR, Pettigrew C, Soldan A, Albert MS, Walston JD. Plasma markers of inflammation linked to clinical progression and decline during preclinical AD. Front. Aging Neurosci. 2019; 11. https://doi.org/10.3389/fnagi.2019.00229.
Darweesh SKL, Wolters FJ, Ikram MA, de Wolf F, Bos D, Hofman A. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimer’s Dement. 2018;14:1450–9. https://doi.org/10.1016/j.jalz.2018.02.014.
Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol. 2010;224:93–100.
Lee WJ, Liao YC, Wang YF, Lin IF, Wang SJ, Fuh JL. Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. 2018; 8. https://doi.org/10.1038/s41598-018-19807-y.
Bettcher BM, Neuhaus J, Wynn MJ, Elahi FM, Casaletto KB, Saloner R, Fitch R, Karydas A, Kramer JH. Increases in a Pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time. Front Aging Neurosci. 2019; 10. https://doi.org/10.3389/fnagi.2019.00025.
Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg H, Blennow K, Carlsson CM, Neuhaus J, et al. Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer’s disease pathology and neuronal damage. J Alzheimer’s Dis. 2018;62:385–97. https://doi.org/10.3233/JAD-170602.
Moon JS, Goeminne LJE, Kim JT, Tian JW, Kim SH, Nga HT, Kang SG, Kang BE, Byun JS, Lee YS, et al. Growth differentiation factor 15 protects against the aging-mediated systemic inflammatory response in humans and mice. Aging Cell 2020, 19. https://doi.org/10.1111/acel.13195.
Chang JY, Hong HJ, Kang SG, Kim JT, Zhang BY, Shong M. The role of growth differentiation factor 15 in energy metabolism. Diabetes Metab J. 2020;44:363–71. https://doi.org/10.4093/dmj.2020.0087.
Fuchs T, Trollor JN, Crawford J, Brown DA, Baune BT, Samaras K, Campbell L, Breit SN, Brodaty H, Sachdev P, et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell. 2013;12:882–9. https://doi.org/10.1111/acel.12116.
McGrath ER, Himali JJ, Levy D, Conner SC, DeCarli C, Pase MP, Ninomiya T, Ohara T, Courchesne P, Satizabal CL, et al. Growth differentiation factor 15 and NT-proBNP as blood-based markers of vascular brain injury and dementia. J Am Heart Assoc. 2020;9:e014659. https://doi.org/10.1161/JAHA.119.014659.
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.
Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, Sarasa L, Allué JA, Proctor NK, Zetterberg H, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1:114–23. https://doi.org/10.1038/s43587-020-00003-5.
Kaeser SA, Lehallier B, Thinggaard M, Häsler LM, Apel A, Bergmann C, Berdnik D, Jeune B, Christensen K, Grönke S, et al. A neuronal blood marker is associated with mortality in old age. Nat Aging. 2021;1:218–25. https://doi.org/10.1038/s43587-021-00028-4.
Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, Cuffi MN, Bordes S, Gasnier Y, Robert P, et al. Mapt study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimer’s Dis. 2014;1:13–22. https://doi.org/10.14283/jpad.2014.34.
Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–89. https://doi.org/10.1016/S1474-4422(17)30040-6.
Morris JC. The clinical dementia rating (cdr): Current version and scoring rules. Neurology. 1993;43:2412–4. https://doi.org/10.1212/wnl.43.11.2412-a.
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961–70. https://doi.org/10.1001/jamaneurol.2014.803.
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5.
Coley N, Gallini A, Ousset PJ, Vellas B, Andrieu S. Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer’s prevention trial. Alzheimer’s Dement. 2016;12:1216–25. https://doi.org/10.1016/j.jalz.2016.06.002.
Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.
Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4.
Newson RB. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stata J. 2010;10:339–58.
Matthew C. Pointwise confidence intervals for the covariate-adjusted survivor function in the Cox model. Stata J. 2011;11:64–81. https://doi.org/10.1177/1536867X19830915.
Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach. 2nd ed. New York: Springer; 2002.
Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in chronic heart failure. Circ Hear Fail. 2012;5:183–90. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965020.
Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R, Mörtl D, Maurer G, Pacher R, Huber K, et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2013;168:1251–7. https://doi.org/10.1016/j.ijcard.2012.11.052.
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194.
Van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, Van Der Flier WM. Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) project. JAMA Neurol. 2017;74:1481–91. https://doi.org/10.1001/jamaneurol.2017.2712.
van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019;18:1034–44. https://doi.org/10.1016/S1474-4422(19)30283-2.
Wallace LMK, Theou O, Godin J, Andrew MK, Bennett DA, Rockwood K. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer’s disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. Lancet Neurol. 2019;18:177–84. https://doi.org/10.1016/S1474-4422(18)30371-5.
Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252–65. https://doi.org/10.1111/j.1600-0447.2008.01326.x.
Buchhave P, Minthon L, Zetterberg H, Wallin ÅK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98–106. https://doi.org/10.1001/archgenpsychiatry.2011.155.
Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, et al. Plasma amyloid-β and risk of Alzheimer’s disease in the Framingham Heart Study. Alzheimer’s Dement. 2015;11:249-257.e1. https://doi.org/10.1016/j.jalz.2014.07.001.
Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008;29:1–11. https://doi.org/10.1016/j.neurobiolaging.2006.09.002.
Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in alzheimer’s disease. Brain Pathol. 2009;19:392–8. https://doi.org/10.1111/j.1750-3639.2008.00188.x.
Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, Herzog EL, Kang I, Pisani MA, Yu S, et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178:1231-1244.e11. https://doi.org/10.1016/j.cell.2019.07.033.
Wollert KC. Growth-differentiation factor-15 in cardiovascular disease. Basic Res Cardiol. 2007;102:412–5.
Baek SJ, Eling T. Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases. Pharmacol Ther. 2019;198:46–58. https://doi.org/10.1016/j.pharmthera.2019.02.008.
Corre J, Hébraud B, Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med. 2013;2:946–52. https://doi.org/10.5966/sctm.2013-0055.
Tavenier J, Rasmussen LJH, Andersen AL, Houlind MB, Langkilde A, Andersen O, Petersen J, Nehlin JO. Association of GDF15 with inflammation and physical function during aging and recovery after acute hospitalization: a longitudinal study of older patients and Age-matched controls. Journals Gerontol Ser A. 2021;76:964–74. https://doi.org/10.1093/gerona/glab011.
Jiang J, Wen W, Sachdev PS. Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia. Curr Opin Psychiatry. 2016;29:181–6.
Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M. Secreted growth differentiation factor15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int. 2016;16:17–29.
Acknowledgements
We acknowledge Christelle Cantet at CERPOP, UMR1295, Inserm Université Toulouse III, for her thoughtful suggestions and confirmation of our statistical modeling approach and interpretation.
Members of the MAPT/DSA group include:
MAPT/DSA group
MAPT Study group: principal investigator, Bruno Vellas (Toulouse); coordination, Sophie Guyonnet; project leader, Isabelle Carrié; CRA, Lauréane Brigitte; investigators, Catherine Faisant, Françoise Lala, Julien Delrieu, Hélène Villars; psychologists, Emeline Combrouze, Carole Badufle, Audrey Zueras; methodology, statistical analysis, and data management, Sandrine Andrieu, Christelle Cantet, Christophe Morin; multidomain group, Gabor Abellan Van Kan, Charlotte Dupuy, Yves Rolland (physical and nutritional components), Céline Caillaud, Pierre-Jean Ousset (cognitive component), Françoise Lala (preventive consultation) (Toulouse). The cognitive component was designed in collaboration with Sherry Willis from the University of Seattle and Sylvie Belleville, Brigitte Gilbert, and Francine Fontaine from the University of Montreal.
Co-investigators in associated centers, Jean-François Dartigues, Isabelle Marcet, Fleur Delva, Alexandra Foubert, Sandrine Cerda (Bordeaux); Marie-Noëlle-Cuffi, Corinne Costes (Castres); Olivier Rouaud, Patrick Manckoundia, Valérie Quipourt, Sophie Marilier, Evelyne Franon (Dijon); Lawrence Bories, Marie-Laure Pader, Marie-France Basset, Bruno Lapoujade, Valérie Faure, Michael Li Yung Tong, Christine Malick-Loiseau, Evelyne Cazaban-Campistron (Foix); Françoise Desclaux, Colette Blatge (Lavaur); Thierry Dantoine, Cécile Laubarie-Mouret, Isabelle Saulnier, Jean-Pierre Clément, Marie-Agnès Picat, Laurence Bernard-Bourzeix, Stéphanie Willebois, Iléana Désormais, Noëlle Cardinaud (Limoges); Marc Bonnefoy, Pierre Livet, Pascale Rebaudet, Claire Gédéon, Catherine Burdet, Flavien Terracol (Lyon), Alain Pesce, Stéphanie Roth, Sylvie Chaillou, Sandrine Louchart (Monaco); Kristel Sudres, Nicolas Lebrun, Nadège Barro-Belaygues (Montauban); Jacques Touchon, Karim Bennys, Audrey Gabelle, Aurélia Romano, Lynda Touati, Cécilia Marelli, Cécile Pays (Montpellier); Philippe Robert, Franck Le Duff, Claire Gervais, Sébastien Gonfrier (Nice); Yannick Gasnier and Serge Bordes, Danièle Begorre, Christian Carpuat, Khaled Khales, Jean-François Lefebvre, Samira Misbah El Idrissi, Pierre Skolil, Jean-Pierre Salles (Tarbes).
MRI group: Carole Dufouil (Bordeaux), Stéphane Lehéricy, Marie Chupin, Jean-François Mangin, Ali Bouhayia (Paris); Michèle Allard (Bordeaux); Frédéric Ricolfi (Dijon); Dominique Dubois (Foix); Marie Paule Bonceour Martel (Limoges); François Cotton (Lyon); Alain Bonafé (Montpellier); Stéphane Chanalet (Nice); Françoise Hugon (Tarbes); Fabrice Bonneville, Christophe Cognard, François Chollet (Toulouse).
PET scan group: Pierre Payoux, Thierry Voisin, Julien Delrieu, Sophie Peiffer, Anne Hitzel, (Toulouse); Michèle Allard (Bordeaux); Michel Zanca (Montpellier); Jacques Monteil (Limoges); Jacques Darcourt (Nice).
Medico-economics group: Laurent Molinier, Hélène Derumeaux, Nadège Costa (Toulouse).
Biological sample collection: Bertrand Perret, Claire Vinel, Sylvie Caspar-Bauguil (Toulouse).
Safety management: Pascale Olivier-Abbal.
DSA Group: Sandrine Andrieu, Christelle Cantet, Nicola Coley.
Funding
The present work was performed in the context of the Inspire Program, a research platform supported by grants from the Region Occitanie/Pyrénées-Méditerranée (Reference number: 1901175) and the European Regional Development Fund (ERDF) (Project number: MP0022856). This study received funds from Alzheimer Prevention in Occitania and Catalonia (APOC Chair of Excellence – Inspire Program). This study has been partially supported through the grant EUR CARe N°ANR-18-EURE-0003 in the framework of the Programme des Investissements d'Avenir. The plasma measures of this study were supported by institutional gift funds (RJ Bateman, PI), institutional startup funds (AD Nguyen, PI), and National Institute on Aging grants NIH R56AG061900 and RF1AG061900 (RJ Bateman, PI). The MAPT study was supported by grants from the Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008, 2009), Pierre Fabre Research Institute (manufacturer of the omega-3 supplement), ExonHit Therapeutics SA, and Avid Radiopharmaceuticals Inc. The promotion of this study was supported by the University Hospital Center of Toulouse. The data sharing activity was supported by the Association Monegasque pour la Recherche sur la maladie d’Alzheimer (AMPA) and the INSERM-University of Toulouse III UMR 1295 Unit.
Author information
Authors and Affiliations
Consortia
Contributions
Conceptualization, W-HL and PSB; methodology, W-HL and PSB; formal analysis, W-HL; investigation, JEM, AP, GA, ADN, YL, and RJB; data curation, W-HL; writing—original draft preparation, W-HL; writing—review and editing, KVG, JEM, SG, AP, GA, ADN, YL, RJB, BV, and PSB; supervision, BV and PSB; funding acquisition, ADN, RJB, and BV.
Ethics declarations
Ethics approval
The MAPT Study was approved by the French Ethical Committee located in Toulouse (CPP SOOM II) and authorized by the French Health Authority. All participants signed informed consent.
Conflict of interest
Washington University and Randall Bateman have equity ownership interest in C2N Diagnostics and receive income based on technology (blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with RJB as co-inventor, has submitted the US nonprovisional patent application “Plasma Based Methods for Determining A-Beta Amyloidosis.” RJB has received honoraria as a speaker/consultant/advisory board member from Amgen, AC Immune, Eisai, and Hoffman-LaRoche, and reimbursement of travel expenses from AC Immune.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Lu, WH., Giudici, K.V., Morley, J.E. et al. Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. GeroScience 44, 1489–1503 (2022). https://doi.org/10.1007/s11357-022-00554-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-022-00554-y